An In Vitro Diagnostic Test for Dose Maintenance Setting in Patients Treated with Concizumab
Time: 2:00 pm
day: Day 1 - Track B (1)
Details:
- Concizumab is an anti TFPI monoclonal antibody intended for all haemophilia A and B types
- Treatment with concizumab require dose maintenance setting based on concizumab exposure levels 4 weeks after treatment initiation using an IVD
- A ConcizuTrace ELISA test access solution provides a complete service portal for CDx test ordering and CDx test result provision
